PURPOSE: This study aims to develop a molecular imaging strategy for response assessment of arginine deiminase (ADI) treatment in melanoma xenografts using 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]-FLT) positron emission tomography (PET). PROCEDURES: F-FLT response to ADI therapy was studied in preclinical models of melanoma in vitro and in vivo. The molecular mechanism of response to ADI therapy was investigated, with a particular emphasis on biological pathways known to regulate (18)F-FLT metabolism. RESULTS: Proliferation of SK-MEL-28 melanoma tumors was potently inhibited by ADI treatment. However, no metabolic response was observed in FLT PET, presumably based on the known ADI-induced degradation of PTEN, followed by instability of the tumor suppressor p53 and a relative overexpression of thymidine kinase 1, the enzyme mainly responsible for intracellular FLT processing. CONCLUSION: The specific pharmacological properties of ADI preclude using (18)F-FLT to evaluate clinical response in melanoma and argue for further studies to explore the use of other clinically applicable PET tracers in ADI treatment.
PURPOSE: This study aims to develop a molecular imaging strategy for response assessment of arginine deiminase (ADI) treatment in melanoma xenografts using 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]-FLT) positron emission tomography (PET). PROCEDURES: F-FLT response to ADI therapy was studied in preclinical models of melanoma in vitro and in vivo. The molecular mechanism of response to ADI therapy was investigated, with a particular emphasis on biological pathways known to regulate (18)F-FLT metabolism. RESULTS: Proliferation of SK-MEL-28 melanoma tumors was potently inhibited by ADI treatment. However, no metabolic response was observed in FLT PET, presumably based on the known ADI-induced degradation of PTEN, followed by instability of the tumor suppressor p53 and a relative overexpression of thymidine kinase 1, the enzyme mainly responsible for intracellular FLT processing. CONCLUSION: The specific pharmacological properties of ADI preclude using (18)F-FLT to evaluate clinical response in melanoma and argue for further studies to explore the use of other clinically applicable PET tracers in ADI treatment.
Authors: Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga Journal: Eur J Nucl Med Mol Imaging Date: 2004-12 Impact factor: 9.236
Authors: Evan S Glazer; Mauro Piccirillo; Vittorio Albino; Raimondo Di Giacomo; Raffaele Palaia; Angelo A Mastro; Gerardo Beneduce; Giuseppe Castello; Vincenzo De Rosa; Antonella Petrillo; Paolo A Ascierto; Steven A Curley; Francesco Izzo Journal: J Clin Oncol Date: 2010-03-29 Impact factor: 44.544
Authors: Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; Sarah M Dry; Piriya Sutthiruangwong; Claudio Spick; Caius Radu; Wolfgang A Weber; William D Tap; Fritz C Eilber Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Randie H Kim; Jodi M Coates; Tawnya L Bowles; Gregory P McNerney; Julie Sutcliffe; Jae U Jung; Regina Gandour-Edwards; Frank Y S Chuang; Richard J Bold; Hsing-Jien Kung Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: N Syed; J Langer; K Janczar; P Singh; C Lo Nigro; L Lattanzio; H M Coley; E Hatzimichael; J Bomalaski; P Szlosarek; M Awad; K O'Neil; F Roncaroli; T Crook Journal: Cell Death Dis Date: 2013-01-17 Impact factor: 8.469
Authors: Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556
Authors: Emma Beddowes; James Spicer; Pui Ying Chan; Ramsay Khadeir; Javier Garcia Corbacho; Dimitra Repana; Jeremy P Steele; Peter Schmid; Teresa Szyszko; Gary Cook; Monica Diaz; Xiaoxing Feng; Amanda Johnston; Jim Thomson; Michael Sheaff; Bor-Wen Wu; John Bomalaski; Simon Pacey; Peter W Szlosarek Journal: J Clin Oncol Date: 2017-04-07 Impact factor: 44.544
Authors: Shuyang Yao; Filip Janku; Kimberly Koenig; Apostolia Maria Tsimberidou; Sarina Anne Piha-Paul; Nai Shi; John Stewart; Amanda Johnston; John Bomalaski; Funda Meric-Bernstam; Siqing Fu Journal: Cancer Med Date: 2021-11-28 Impact factor: 4.452
Authors: Pui Ying Chan; Melissa M Phillips; Stephen Ellis; Amanda Johnston; Xiaoxing Feng; Amit Arora; Gordon Hay; Victoria M L Cohen; Mandeep S Sagoo; John S Bomalaski; Michael T Sheaff; Peter W Szlosarek Journal: Pigment Cell Melanoma Res Date: 2022-05-16 Impact factor: 4.159
Authors: Teresa A Szyszko; Joel T Dunn; Melissa M Phillips; John Bomalaski; Michael T Sheaff; Steve Ellis; Lucy Pike; Vicky Goh; Gary J R Cook; Peter W Szlosarek Journal: JTO Clin Res Rep Date: 2022-07-20